GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: ARV-471 | ARV471 | compound 341 [WO2018102725A1] | PF-07850327 | PF07850327
                                 
                                                         
                            Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Vepdegrestrant (ARV471) is a bifunctional compound that is estrogen receptor (ER) degrader (PROTAC) [1]. It uses a cereblon-based binder to direct ER protein degradation. ARV471 is orally bioavailable, and is being investigated for potential to treat breast cancer.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| References | 
| 
                                                                         1. Crew AP, Qian Y, Dong H, Wang J,    Hornberger KR, Crews CM. (2018)
                                         Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders. Patent number: WO2018102725A1. Assignee: Arvinas Inc.. Priority date: 01/12/2016. Publication date: 07/06/2018.  | 
                                                                
| 
                                                                         2. Hamilton EP, Ma C, De Laurentiis M, Iwata H, Hurvitz SA, Wander SA, Danso M, Lu DR, Perkins Smith J, Liu Y et al.. (2024)
                                         VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future Oncol, 20 (32): 2447-2455. [PMID:39072356]  |